Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. lifted its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 32.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,019,332 shares of the company’s stock after acquiring an additional 249,659 shares during the quarter. American Century Companies Inc. owned 1.87% of Voyager Therapeutics worth $8,063,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Armistice Capital LLC grew its position in shares of Voyager Therapeutics by 1.4% during the 4th quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after buying an additional 58,000 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter valued at approximately $1,569,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of Voyager Therapeutics by 2.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after purchasing an additional 2,030 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Voyager Therapeutics by 104.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock valued at $97,000 after purchasing an additional 5,311 shares during the period. Finally, Commonwealth Equity Services LLC bought a new position in Voyager Therapeutics during the 1st quarter worth $530,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Down 2.4 %

VYGR stock opened at $6.10 on Tuesday. The company has a 50-day simple moving average of $7.23 and a 200 day simple moving average of $8.06. The company has a market capitalization of $331.80 million, a P/E ratio of -122.00 and a beta of 0.91. Voyager Therapeutics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The company had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same period in the prior year, the business posted ($0.51) EPS. Equities analysts anticipate that Voyager Therapeutics, Inc. will post -1.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Wedbush cut their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $17.83.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.